Search results for "lesion"

showing 10 items of 1094 documents

Fibrous hamartoma of infancy: an Italian multi-institutional experience.

2006

Fibrous hamartoma of infancy: an Italian multi-institutional experience. Carretto E, Dall'Igna P, Alaggio R, Siracusa F, Granata C, Ferrari A, Cecchetto G. Source Division of Paediatric Surgery, Department of Paediatrics, University of Padua, Padua, Italy. Abstract BACKGROUND: Fibrous hamartoma (FH) of infancy is a benign mesenchymal tumor, occurring as a superficial mass. Complete excision is curative. OBJECTIVE AND METHODS: The clinical features and treatment results of 18 children with FH are described. RESULTS: Local excision was the most common procedure. Surgery was radical in 10 patients, with microscopic residual disease in 6; all of them are alive with no evidence of disease 2 to 4…

Malemedicine.medical_specialtymedicine.medical_treatmentBiopsyHamartomaDermatologyDiseaseSkin DiseasesLesionBiopsymedicineFibrous hamartomaHumansChildChemotherapymedicine.diagnostic_testbusiness.industryInfant NewbornInfantLabia majoraSurgeryPlastic surgerymedicine.anatomical_structureTreatment OutcomeItalyChild PreschoolFemalemedicine.symptombusinesspaediatric surgery paediatric tumours fibrohamartomaFibrous hamartoma of infancyJournal of the American Academy of Dermatology
researchProduct

Three-Year Results of Repaired Barlow Mitral Valves via Right Minithoracotomy versus Median Sternotomy in a Randomized Trial

2012

<b><i>Objectives:</i></b> To clarify whether the results of repair of a complex mitral lesion (Barlow valve) at the intermediate-term follow-up are independent of the mode of surgical access [minithoracotomy vs. median sternotomy (MS)]. <b><i>Methods:</i></b> In a prospective randomized study of mitral repair for Barlow disease using either a minimally invasive (MI) approach or MS, we achieved an average follow-up of 3 years (echocardiography, physical examination and quality of life). Mitral repair was achieved with polytetrafluoroethylene chordal implantation for both leaflets. <b><i>Results:</i></b> Both groups inclu…

Malemedicine.medical_specialtymedicine.medical_treatmentFollow-Up Studielaw.inventionLesionRandomized controlled trialMinimally invasive surgerylawmedicineHumansMitral Valve StenosisPharmacology (medical)Prospective StudiesMitral Valve Stenosicardiovascular diseasesMitral valve repairMitral Valve Prolapsebusiness.industryFollow-upMedicine (all)Mitral Valve InsufficiencyGenetic Diseases X-LinkedMiddle AgedSternotomySurgeryProspective StudieTreatment OutcomeThoracotomyMedian sternotomyQuality of Lifecardiovascular systemMitral ValveFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessMitral valve repairFollow-Up StudiesHumanCardiology
researchProduct

The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein …

2013

The objective of this study was to evaluate whether the presence of a plasminogen activator inhibitor type 1 (PAI-1) promoter polymorphism 4G/5G could significantly influence the proximal extension of vein thrombosis in spite of anticoagulant treatment in patients with calf vein thrombosis (CVT) following orthopaedic, urological and abdominal surgery. We studied 168 patients with CVT, who had undergone orthopaedic, urological and abdominal surgery, subdivided as follows: first, 50 patients with thrombosis progression; second, 118 patients without thrombosis progression. The 4G/5G polymorphism of the plasminogen activator inhibitor 1 was evaluated in all patients and in 70 healthy matched co…

Malemedicine.medical_specialtymedicine.medical_treatmentGastroenterologychemistry.chemical_compoundPostoperative ComplicationsGene FrequencyRisk FactorsInternal medicineFibrinolysisPlasminogen Activator Inhibitor 1Factor V LeidenmedicineOdds RatioHumansGenetic Predisposition to Disease4G/5G genotype PAI-1 thrombotic lesionsPromoter Regions GeneticAllelesAgedVenous ThrombosisPolymorphism Geneticbusiness.industryHematologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseNadroparin calciumThrombosisSurgerychemistryPlasminogen activator inhibitor-1Case-Control StudiesFemalebusinessPlasminogen activatorAbdominal surgerymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Cell-free DNA and Microvascular Damage in ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention.

2019

INTRODUCTION AND OBJECTIVES Cell-free DNA (cfDNA) in ST-segment elevation myocardial infarction might originate from hyperactivated leukocytes at the coronary lesion. Our aim was to investigate the relationship between cfDNA and coronary reperfusion. METHODS We studied 116 patients treated with primary angioplasty using thrombus aspiration. Coronary (during aspiration) and peripheral (at the end of the procedure) blood samples were drawn for cfDNA, as well as high-sensitivity troponin T and myeloperoxidase quantification. The primary endpoint was no ST-segment resolution (STR) (≥ 70%) and the secondary endpoint was lack of final Thrombolysis In Myocardial Infarction flow 3 (TIMI 3). RESULTS…

Malemedicine.medical_specialtymedicine.medical_treatmentMyocardial ReperfusionMyocardial Reperfusion Injury030204 cardiovascular system & hematologyLymphocyte ActivationLesion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionTroponin TInternal medicinemedicineClinical endpointLeukocytesST segmentHumanscardiovascular diseasesMyocardial infarctionProspective StudiesPeroxidaseTroponin Tbusiness.industryPercutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedmedicine.diseaseTreatment OutcomeMicrovesselsCardiologyST Elevation Myocardial InfarctionFemalemedicine.symptombusinessCell-Free Nucleic AcidsTIMIRevista espanola de cardiologia (English ed.)
researchProduct

A case of post-traumatic complex auditory hallucinosis treated with rTMS.

2010

Previous studies of auditory hallucinations in schizophrenia found that the hallucinations were reduced by the application of transcranial magnetic stimulation (rTMS). Here we describe a case of traumatic brain injury associated with continuous music hallucinations. An MRI scan showed a structural lesion of the right temporal pole and a PET scan indicated a hyperactive area of the posterior right temporal lobe. We hypothesized that rTMS applied to the right temporal area would reduce this activity and the corresponding hallucinations. The patient's music hallucinations were significantly reduced by rTMS treatment. A PET scan following treatment also indicated that rTMS treatment reduced bra…

Malemedicine.medical_specialtypost-traumatic complex auditory hallucinosis rTMS.HallucinationsTraumatic brain injuryBrain activity and meditationmedicine.medical_treatmentAudiologybehavioral disciplines and activitiesHallucinosisSettore BIO/09 - FisiologiaTemporal lobeLesionArts and Humanities (miscellaneous)mental disordersmedicineHumansmedicine.diagnostic_testSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaMagnetic resonance imagingMiddle Agedmedicine.diseaseMagnetic Resonance ImagingTranscranial Magnetic StimulationTemporal LobeTranscranial magnetic stimulationSchizophreniaBrain InjuriesPositron-Emission TomographySettore MED/26 - NeurologiaNeurology (clinical)medicine.symptomPsychologyNeuroscienceMusic
researchProduct

Multiparametric MRI and post implant CT-based dosimetry after prostate brachytherapy with iodine seeds: The higher the dose to the dominant index les…

2015

Abstract Purpose To determine whether post-implant MRI-based dosimetry of the Dominant Intra-prostatic Lesion (DIL) could best predict the occurrence of PSA bounce after prostate brachytherapy. Methods and materials We selected 66 patients with a low risk prostate cancer treated with 125 I prostate brachytherapy as monotherapy. Post-implant dosimetry based on day 30 CT-scan and multiparametric MRI co-registration was generated: planned D 90, D 95, V 100, V 150 values were calculated for each DIL. Bounce was defined as a PSA elevation ⩾0.2ng/mL from the previous baseline value followed by a decrease to or below the prior nadir with no additional treatment. Results After a median follow-up of…

Malemedicine.medical_treatmentBrachytherapyBrachytherapyIodine RadioisotopesProstate cancerProstatemedicineHumansDosimetryRadiology Nuclear Medicine and imagingRadiometryAgedRetrospective StudiesIndex Lesionmedicine.diagnostic_testbusiness.industryProstateProstatic NeoplasmsRadiotherapy DosageMagnetic resonance imagingHematologyMiddle AgedProstate-Specific Antigenmedicine.diseaseMagnetic Resonance ImagingProstate-specific antigenTreatment Outcomemedicine.anatomical_structureOncologyTomography X-Ray ComputedNuclear medicinebusinessProstate brachytherapyFollow-Up StudiesRadiotherapy and Oncology
researchProduct

A Multiplex Panel of Plasma Markers of Immunity and Inflammation in Classical Kaposi Sarcoma

2014

Kaposi sarcoma (KS) risk is affected by perturbed immunity. Herein, we compared plasma from 15 human immunodeficiency virus (HIV)–negative classic KS cases to plasma from 29 matched controls, using a multiplex panel of immunity markers. Of 70 markers, CXCL10 (IP-10), sIL-1RII, sIL-2RA, and CCL3 (MIP-1A) were strongly and significantly associated with KS, after adjustment for age and smoking status. These and previous observations are consistent with a tumor-promoting role for these cytokines, particularly CXCL10, but the small sample size and case-control design preclude firm conclusions on KS risk or pathogenesis. Larger, well-designed prospective studies are needed to better assess the as…

Malemedicine.medical_treatmentInflammationBiologySettore MED/42 - Igiene Generale E ApplicataPathogenesisKaposi SarcomaPlasma Markers of InflammationMajor Articles and Brief ReportsImmunitymedicineHumansImmunology and AllergyProspective cohort studySarcoma KaposiInflammationCase-control studyvirus diseasesPlasma Markers of Immunitymedicine.diseaseSquamous intraepithelial lesionInfectious DiseasesCytokineItalyCase-Control StudiesImmunologySarcomamedicine.symptomBiomarkers
researchProduct

Oculoectodermal syndrome: Report of a new case with a broad clinical spectrum

2014

Oculoectodermal syndrome (OMIM 600268) is rare and characterized by aplasia cutis congenita, epibulbar dermoids, and other abnormalities. We report herein on a newly recognized patient with oculoectodermal syndrome, which is the 19th reported patient with OES. The boy aged six years demonstrated a broad clinical spectrum of this condition, including aplasia cutis congenita, epibulbar dermoids, hyperkeratotic papule, mildly enlarged cisterna magna, and an enlarged fluid space in the quadrigeminal cistern, suggesting a cyst. He also manifested anomalies not reported associated with this disorder, including systematized epidermal nevus following Blaschko's lines, hypopigmented skin lesions, an…

Malemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAplasia cutis congenitaHypopigmented skin lesionsEctodermal DysplasiaOculoectodermal syndromeGeneticsmedicineHumansCystGenetics (clinical)Dermoid CystSkinHyperkeratotic papuleHypopigmentationSystematized epidermal nevusbusiness.industryEpibulbar dermoidsBrainmedicine.diseaseMagnetic Resonance ImagingDermatologyEnlarged cisterna magnaPhenotypeChild Preschoolmedicine.symptombusinessAmerican Journal of Medical Genetics Part A
researchProduct

Cognitive Reserve Proxies Do Not Differentially Account for Cognitive Performance in Patients with Focal Frontal and Non-Frontal Lesions

2020

AbstractObjective:Cognitive reserve (CR) suggests that premorbid efficacy, aptitude, and flexibility of cognitive processing can aid the brain’s ability to cope with change or damage. Our previous work has shown that age and literacy attainment predict the cognitive performance of frontal patients on frontal-executive tests. However, it remains unknown whether CR also predicts the cognitive performance of non-frontal patients.Method:We investigated the independent effect of a CR proxy, National Adult Reading Test (NART) IQ, as well as age and lesion group (frontal vs. non-frontal) on measures of executive function, intelligence, processing speed, and naming in 166 patients with focal, unila…

Maleneuropsychological testsaetiologyIntelligenceNeuropsychological TestsAudiologyExecutive Function0302 clinical medicineAetiologynon-frontal lesionCognitive reservemedia_commonIntelligence TestsBrain NeoplasmsGeneral Neuroscience05 social sciencesFlexibility (personality)CognitionMiddle AgedNeuropsychological testcognitive reserveFrontal LobeStrokePsychiatry and Mental healthClinical PsychologyFemaleAptitudemedicine.symptomPsychologyAdultNon-frontal lesionmedicine.medical_specialtyFrontal lesionmedia_common.quotation_subjectCognitive reserveContext (language use)Brain damageNational Adult Reading Testbehavioral disciplines and activities050105 experimental psychologyYoung Adult03 medical and health sciencesAgemedicineHumans0501 psychology and cognitive sciencesEffects of sleep deprivation on cognitive performanceAgedSettore M-PSI/02 - Psicobiologia E Psicologia Fisiologicafrontal lesionReadingageBrain InjuriesCase-Control StudiesNeurology (clinical)Cognition Disorders030217 neurology & neurosurgeryJournal of the International Neuropsychological Society
researchProduct

Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

2021

Background and purpose: Tumefactive multiple sclerosis (TuMS) (i.e., MS onset presenting with tumefactive demyelinating lesions [TDLs]) is a diagnostic and therapeutic challenge. We performed a multicentre retrospective study to describe the clinical characteristics and the prognostic factors of TuMS. Methods: One hundred two TuMS patients were included in this retrospective study. Demographic, clinical, magnetic resonance imaging (MRI), laboratory data and treatment choices were collected. Results: TuMS was found to affect women more than men (female:male: 2.4), with a young adulthood onset (median age: 29.5 years, range: 11–68 years, interquartile range [IQR]: 38 years). At onset, 52% of …

Maletumefactive demyelinating lesions (TDLs)0302 clinical medicineRetrospective StudieInterquartile rangedifferential diagnosis030212 general & internal medicineProspective StudiesYoung adultProspective cohort studyChildtreatmentTumefactive multiple sclerosiTumefactive demyelinating lesionsDemyelinating DiseaseMiddle AgedMagnetic Resonance ImagingDifferential diagnosis Multiple sclerosis Tumefactive demyelinating lesions Tumefactive multiple sclerosisNeurologydifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosisFemaleHumanAdultmedicine.medical_specialtyMultiple SclerosisAdolescentdifferential diagnosiSettore MED/26Multiple sclerosis03 medical and health sciencesYoung AdultTumefactive multiple sclerosisOligoclonal BandInternal medicinemedicineHumansMultiple sclerosiTumefactive multiple sclerosisTumefactive multiple sclerosis (TuMS)AgedRetrospective StudiesTumefactive demyelinating lesionExpanded Disability Status Scalebusiness.industryOligoclonal BandsRetrospective cohort studyOdds ratiomedicine.diseaseConfidence intervalProspective Studiedifferential diagnosis; Multiple sclerosis; Tumefactive demyelinating lesions; Tumefactive multiple sclerosis; Adolescent; Adult; Aged; Child; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Oligoclonal Bands; Prospective Studies; Retrospective Studies; Young Adult; Demyelinating Diseases; Multiple SclerosisprognosisNeurology (clinical)business030217 neurology & neurosurgeryDemyelinating Diseases
researchProduct